Effect of Baricitinib Treatment on Peripheral Bone in RA

Summary

Patients with Rheumatoid Arthritis (RA) suffer systemic and peripheral bone loss. In this study we aim to test the efficacy of in-label treatment with Baricitinib on the volumetric bone mineral density in patients with RA over 52 weeks. Inclusion of RA patients comprises pathologic volumetric bone mineral density measured by (High Resolution peripheral quantitative Computed Tomomgraphy) HR-pQCT maging of finger joints.

Timeline

Start

2018-09-11

Primary completion

2021-10-11

Completion

2021-10-11

Publications

• Simon D, Minopoulou I, Kemenes S, Bayat S, Tascilar K, Mutlu MY, Valor-Mendez L, Kronke G, Hueber AJ, Schett G, Kleyer A. Baricitinib Improves Bone Properties and Biomechanics in Patients With Rheumatoid Arthritis: Results of the Prospective Interventional BARE BONE Trial. Arthritis Rheumatol. 2023 Nov;75(11):1923-1934. doi: 10.1002/art.42617. Epub 2023 Sep 21.

Drugs

Indications